We are live on ! Find out more
TGTX icon

TG Therapeutics

309 hedge funds and large institutions have $2.38B invested in TG Therapeutics in 2024 Q3 according to their latest regulatory filings, with 98 funds opening new positions, 93 increasing their positions, 74 reducing their positions, and 44 closing their positions.

New
Increased
Maintained
Reduced
Closed

123% more first-time investments, than exits

New positions opened: 98 | Existing positions closed: 44

52% more call options, than puts

Call options by funds: $70.9M | Put options by funds: $46.8M

51% more capital inflows, than outflows

Capital inflows: $572M | Capital outflows: $379M

26% more repeat investments, than reductions

Existing positions increased: 93 | Existing positions reduced: 74

19% more funds holding

Funds holding: 259 → 309 (+50)

5.13% more ownership

Funds ownership: 60.55% → 65.68% (+5.1%)

17% less funds holding in top 10

Funds holding in top 10: 6 → 5 (-1)

Holders
309
Holders Change
+50
Holders Change %
+19.31%
% of All Funds
4.42%
Holding in Top 10
5
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-16.67%
% of All Funds
0.07%
New
98
Increased
93
Reduced
74
Closed
44
Calls
$70.9​M
Puts
$46.8​M
Net Calls
+$24.2​M
Net Calls Change
+$10.5​M

TGTX Hedge Fund Activity: Q3 2024 in Review

309 of the 6,990 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q3 2024, worth a combined $2.38B — up 42% from $1.67B a quarter earlier.

Buyers outnumbered sellers: 98 funds opened new TGTX positions and 44 closed out — a net gain of 54 holders — while 93 added to existing stakes and 74 trimmed.

The largest buyer was BlackRock, adding an estimated $231M. The largest seller was Citadel Advisors, cutting an estimated $37.9M.

  • 309 institutional investors held TG Therapeutics (TGTX) as of Q3 2024, up from 259 in Q2 2024.
  • Funds reported $2.38B of TG Therapeutics stock for Q3 2024, up 42% quarter-over-quarter.
  • 98 funds opened new TG Therapeutics positions in Q3 2024 and 44 closed out, a net change of +54 holders.
  • The largest TG Therapeutics buyer in Q3 2024 was BlackRock, an estimated $231M added.
  • The largest TG Therapeutics seller in Q3 2024 was Citadel Advisors, an estimated $37.9M sold.

Based on aggregated 13F filings for Q3 2024.